AACR 2023

DDW’s Megan Thomas provides highlights from AACR 2023, the American Association of Cancer Research’s annual meeting from 14-19 April 2023 in Orlando, Florida, US.  Meet the incoming AACR President  Having said goodbye and thank you to Dr Lisa Coussens, AACR President for 2022-2023, Dr Philip Greenberg was inaugurated as President at this year’s meeting to […]

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The news stories dominating the headlines this week have been the breaking developments in cancer drug discovery announced at the American Association of […]

News round-up for 16-21 April by DDW Digital Content Editor Diana Spencer. The news stories dominating the headlines this week have been the breaking developments in cancer drug discovery announced at the American Association of Cancer Research (AACR) Annual Meeting, which was held in Florida, US from 14-19 April. The event showcased the very latest […]

New study results have demonstrated the potential of a new drug to reprogramme the immune profile in the tumour microenvironment (TME) and convert resistant tumours to responders to Immune Checkpoint Blockage (ICB) therapies. Purple Biotech shared the new results at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Florida, US. The study […]

Tisch Cancer Center scientists have developed unique models of acute myeloid leukaemia (AML), creating a transformative resource to study this cancer and eventually its drug response and drug resistance. The research was presented at the annual meeting of the American Association of Cancer Research and simultaneously published in Blood Cancer Discovery, a journal of the […]

UK company Macomics presented data demonstrating its Enigmac macrophage drug discovery platform at the American Association for Cancer Research’s Annual Meeting (AACR) in Florida. The company uses macrophage-based approaches to develop novel precision medicines to target disease specific macrophage biology. Macrophages are key players of the tumour microenvironment (TME). Most tumours are populated by macrophages […]

The AACR Annual Meeting’s second clinical trials plenary session, ‘Hope for Rare Cancers: Novel Targeted and Immunotherapy Agents’, highlighted promising studies that suggest new treatment approaches for rare cancers. First Hippo-YAP pathway inhibitor shows success in advanced solid tumours Timothy A Yap reported on a study that provides the first clinical proof-of-concept for effectively drugging […]

DDW’s Megan Thomas rounds up highlights from Tuesday 17 April at AACR 2023, from AI and mathematical oncology to winners of the AACR James S Ewing-Thelma B Dunn Award for Outstanding Achievement in Pathology in Cancer Research. Clinical announcements Promising results for olaparib plus ceralasertib Today, results from the Phase I portion of the Phase […]

Exome sequencing correctly identified individuals with cancer predisposition syndromes who would have been missed by current screening guidelines, according to results from the Tapestry clinical trial. Data presented at the AACR Annual Meeting 2023 showed that among individuals who consented to whole-exome sequencing and were identified as carriers of predisposition genes for hereditary breast and […]

A combination of the PARP inhibitor olaparib (Lynparza) and the investigational ATR inhibitor ceralasertib showed clinical benefit in paediatric patients with solid tumours exhibiting DNA replication stress and/or DNA repair deficiencies, according to new data. The results from the Phase I portion of the Phase I/II AcSé-ESMART trial were presented at the AACR Annual Meeting […]